Taking people in Spanyolország1/2. fázis
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
Key facts
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife és Valencia, SpanyolországSee the 10 sites
- Phase
- 1/2. fázis
Where in Spanyolország
- Hospital Germans Trias i PujolBadalona, SpanyolországTaking people
- Hospital del MarBarcelona, SpanyolországTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországTaking people
- El Hospital Universitario De Gran Canaria Dr. NegrinLas Palmas De Gran Canaria, SpanyolországTaking people
- Hospital Universitario Regional de MálagaMálaga, SpanyolországTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpanyolországTaking people
- Clínica Universidad de navarraPamplona, SpanyolországTaking people
- Hospital Universitario de NavarraPamplona, SpanyolországTaking people
- Hospital Universitario Nuestra Señora de CandelariaSanta Cruz de Tenerife, SpanyolországTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Idp Discovery Pharma S.L.
- Trial code
- EU 2025-521902-17-00
- Record updated
- 2026. május 4.
- Original description
Dose-Escalation Phase (Phase 1) Primary objective: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 combined with chemotherapy (topotecan day 1 to 5 every 3 weeks; carboplatin day 1 plus etoposide days 1, 2 and 3 every 3 weeks) in patients with SCLC. Expansion Phase (Phase 2): Primary objective To evaluate the overall response rate (ORR) and disease control rate (DCR) of IDP-121 combined with chemotherapy in patients with SCLC.Read full original descriptionShow less
Dose-Escalation Phase (Phase 1) Primary objective: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 combined with chemotherapy (topotecan day 1 to 5 every 3 weeks; carboplatin day 1 plus etoposide days 1, 2 and 3 every 3 weeks) in patients with SCLC. Expansion Phase (Phase 2): Primary objective To evaluate the overall response rate (ORR) and disease control rate (DCR) of IDP-121 combined with chemotherapy in patients with SCLC.